Drug allergy passport and other documentation for patients with drug hypersensitivity: An ENDA/EAACI Drug Allergy Interest Group Position Paper

Knut Brockow; Werner Aberer; M Atanaskovic-Markovic; Sevim Bavbek; Andreas Bircher; Beatrice M Bilo; Miguel Blanca; Patrizia Bonadonna; G Burbach; G Calogiuri; C. Caruso; G Celik; J Cernadas; A M Chiriac; P Demoly; J N G Oude Elberink; J Fernandez; E. Gomès; L H Garvey; J Gooi; M Gotua; M Grosber; P Kauppi; V Kvedariene; J. Gómez-Laguna; J S Makowska; H Mosbech; A Nakonechna; N G Papadopolous; J Ring; A Romano; H Rockmann; R Sargur; L Sedlackova; S Sigurdardottir; Benno Schnyder; T Storaas; Mina Torres; M Zidarn; Ingrid Terreehorst

doi:10.1111/all.12929

Drug allergy passport and other documentation for patients with drug hypersensitivity: An ENDA/EAACI Drug Allergy Interest Group Position Paper

Knut Brockow, Werner Aberer, M Atanaskovic-Markovic, Sevim Bavbek, Andreas Bircher, Beatrice M Bilo, Miguel Blanca, Patrizia Bonadonna, G Burbach, G Calogiuri, C. Caruso, G Celik, J Cernadas, A M Chiriac, P Demoly, J N G Oude Elberink, J Fernandez, E. Gomès, L H Garvey, J GooiM Gotua, M Grosber, P Kauppi, V Kvedariene, J. Gómez-Laguna, J S Makowska, H Mosbech, A Nakonechna, N G Papadopolous, J Ring, A Romano, H Rockmann, R Sargur, L Sedlackova, S Sigurdardottir, Benno Schnyder, T Storaas, Mina Torres, M Zidarn, Ingrid Terreehorst

Department of Drug Design and Pharmacology

30 Citations (Scopus)

Abstract

The strongest and best-documented risk factor for drug hypersensitivity (DH) is the history of a previous reaction. Accidental exposures to drugs may lead to severe or even fatal reactions in sensitized patients. Preventable prescription errors are common. They are often due to inadequate medical history or poor risk assessment of recurrence of drug reaction. Proper documentation is essential information for the doctor to make sound therapeutic decision. The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology have formed a task force and developed a drug allergy passport as well as general guidelines of drug allergy documentation. A drug allergy passport, a drug allergy alert card, a certificate, and a discharge letter after medical evaluation are adequate means to document DH in a patient. They are to be handed to the patient who is advised to carry the documentation at all times especially when away from home. A drug allergy passport should at least contain information on the culprit drug(s) including international nonproprietary name, clinical manifestations including severity, diagnostic measures, potential cross-reactivity, alternative drugs to prescribe, and where more detailed information can be obtained from the issuer. It should be given to patients only after full allergy workup. In the future, electronic prescription systems with alert functions will become more common and should include the same information as in paper-based documentation.

Original language	English
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	71
Issue number	11
Pages (from-to)	1533-1539
Number of pages	7
ISSN	0105-4538
DOIs	https://doi.org/10.1111/all.12929
Publication status	Published - 1 Nov 2016

Keywords

Journal Article

Access to Document

10.1111/all.12929

Cite this

Brockow, K., Aberer, W., Atanaskovic-Markovic, M., Bavbek, S., Bircher, A., Bilo, B. M., Blanca, M., Bonadonna, P., Burbach, G., Calogiuri, G., Caruso, C., Celik, G., Cernadas, J., Chiriac, A. M., Demoly, P., Oude Elberink, J. N. G., Fernandez, J., Gomès, E., Garvey, L. H., ... Terreehorst, I. (2016). Drug allergy passport and other documentation for patients with drug hypersensitivity: An ENDA/EAACI Drug Allergy Interest Group Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 71(11), 1533-1539. https://doi.org/10.1111/all.12929

Drug allergy passport and other documentation for patients with drug hypersensitivity: An ENDA/EAACI Drug Allergy Interest Group Position Paper. / Brockow, Knut; Aberer, Werner; Atanaskovic-Markovic, M et al.
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 71, No. 11, 01.11.2016, p. 1533-1539.

Research output: Contribution to journal › Journal article › Research › peer-review

Brockow, K, Aberer, W, Atanaskovic-Markovic, M, Bavbek, S, Bircher, A, Bilo, BM, Blanca, M, Bonadonna, P, Burbach, G, Calogiuri, G, Caruso, C, Celik, G, Cernadas, J, Chiriac, AM, Demoly, P, Oude Elberink, JNG, Fernandez, J, Gomès, E, Garvey, LH, Gooi, J, Gotua, M, Grosber, M, Kauppi, P, Kvedariene, V, Gómez-Laguna, J, Makowska, JS, Mosbech, H, Nakonechna, A, Papadopolous, NG, Ring, J, Romano, A, Rockmann, H, Sargur, R, Sedlackova, L, Sigurdardottir, S, Schnyder, B, Storaas, T, Torres, M, Zidarn, M & Terreehorst, I 2016, 'Drug allergy passport and other documentation for patients with drug hypersensitivity: An ENDA/EAACI Drug Allergy Interest Group Position Paper', Allergy: European Journal of Allergy and Clinical Immunology, vol. 71, no. 11, pp. 1533-1539. https://doi.org/10.1111/all.12929

@article{a33b1651c5aa4ef38743f9f5b579238c,

title = "Drug allergy passport and other documentation for patients with drug hypersensitivity: An ENDA/EAACI Drug Allergy Interest Group Position Paper",

abstract = "The strongest and best-documented risk factor for drug hypersensitivity (DH) is the history of a previous reaction. Accidental exposures to drugs may lead to severe or even fatal reactions in sensitized patients. Preventable prescription errors are common. They are often due to inadequate medical history or poor risk assessment of recurrence of drug reaction. Proper documentation is essential information for the doctor to make sound therapeutic decision. The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology have formed a task force and developed a drug allergy passport as well as general guidelines of drug allergy documentation. A drug allergy passport, a drug allergy alert card, a certificate, and a discharge letter after medical evaluation are adequate means to document DH in a patient. They are to be handed to the patient who is advised to carry the documentation at all times especially when away from home. A drug allergy passport should at least contain information on the culprit drug(s) including international nonproprietary name, clinical manifestations including severity, diagnostic measures, potential cross-reactivity, alternative drugs to prescribe, and where more detailed information can be obtained from the issuer. It should be given to patients only after full allergy workup. In the future, electronic prescription systems with alert functions will become more common and should include the same information as in paper-based documentation.",

keywords = "Journal Article",

author = "Knut Brockow and Werner Aberer and M Atanaskovic-Markovic and Sevim Bavbek and Andreas Bircher and Bilo, {Beatrice M} and Miguel Blanca and Patrizia Bonadonna and G Burbach and G Calogiuri and C. Caruso and G Celik and J Cernadas and Chiriac, {A M} and P Demoly and {Oude Elberink}, {J N G} and J Fernandez and E. Gom{\`e}s and Garvey, {L H} and J Gooi and M Gotua and M Grosber and P Kauppi and V Kvedariene and J. G{\'o}mez-Laguna and Makowska, {J S} and H Mosbech and A Nakonechna and Papadopolous, {N G} and J Ring and A Romano and H Rockmann and R Sargur and L Sedlackova and S Sigurdardottir and Benno Schnyder and T Storaas and Mina Torres and M Zidarn and Ingrid Terreehorst",

note = "{\textcopyright} 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",

year = "2016",

month = nov,

day = "1",

doi = "10.1111/all.12929",

language = "English",

volume = "71",

pages = "1533--1539",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley Online",

number = "11",

}

TY - JOUR

T1 - Drug allergy passport and other documentation for patients with drug hypersensitivity

T2 - An ENDA/EAACI Drug Allergy Interest Group Position Paper

AU - Brockow, Knut

AU - Aberer, Werner

AU - Atanaskovic-Markovic, M

AU - Bavbek, Sevim

AU - Bircher, Andreas

AU - Bilo, Beatrice M

AU - Blanca, Miguel

AU - Bonadonna, Patrizia

AU - Burbach, G

AU - Calogiuri, G

AU - Caruso, C.

AU - Celik, G

AU - Cernadas, J

AU - Chiriac, A M

AU - Demoly, P

AU - Oude Elberink, J N G

AU - Fernandez, J

AU - Gomès, E.

AU - Garvey, L H

AU - Gooi, J

AU - Gotua, M

AU - Grosber, M

AU - Kauppi, P

AU - Kvedariene, V

AU - Gómez-Laguna, J.

AU - Makowska, J S

AU - Mosbech, H

AU - Nakonechna, A

AU - Papadopolous, N G

AU - Ring, J

AU - Romano, A

AU - Rockmann, H

AU - Sargur, R

AU - Sedlackova, L

AU - Sigurdardottir, S

AU - Schnyder, Benno

AU - Storaas, T

AU - Torres, Mina

AU - Zidarn, M

AU - Terreehorst, Ingrid

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The strongest and best-documented risk factor for drug hypersensitivity (DH) is the history of a previous reaction. Accidental exposures to drugs may lead to severe or even fatal reactions in sensitized patients. Preventable prescription errors are common. They are often due to inadequate medical history or poor risk assessment of recurrence of drug reaction. Proper documentation is essential information for the doctor to make sound therapeutic decision. The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology have formed a task force and developed a drug allergy passport as well as general guidelines of drug allergy documentation. A drug allergy passport, a drug allergy alert card, a certificate, and a discharge letter after medical evaluation are adequate means to document DH in a patient. They are to be handed to the patient who is advised to carry the documentation at all times especially when away from home. A drug allergy passport should at least contain information on the culprit drug(s) including international nonproprietary name, clinical manifestations including severity, diagnostic measures, potential cross-reactivity, alternative drugs to prescribe, and where more detailed information can be obtained from the issuer. It should be given to patients only after full allergy workup. In the future, electronic prescription systems with alert functions will become more common and should include the same information as in paper-based documentation.

AB - The strongest and best-documented risk factor for drug hypersensitivity (DH) is the history of a previous reaction. Accidental exposures to drugs may lead to severe or even fatal reactions in sensitized patients. Preventable prescription errors are common. They are often due to inadequate medical history or poor risk assessment of recurrence of drug reaction. Proper documentation is essential information for the doctor to make sound therapeutic decision. The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology have formed a task force and developed a drug allergy passport as well as general guidelines of drug allergy documentation. A drug allergy passport, a drug allergy alert card, a certificate, and a discharge letter after medical evaluation are adequate means to document DH in a patient. They are to be handed to the patient who is advised to carry the documentation at all times especially when away from home. A drug allergy passport should at least contain information on the culprit drug(s) including international nonproprietary name, clinical manifestations including severity, diagnostic measures, potential cross-reactivity, alternative drugs to prescribe, and where more detailed information can be obtained from the issuer. It should be given to patients only after full allergy workup. In the future, electronic prescription systems with alert functions will become more common and should include the same information as in paper-based documentation.

KW - Journal Article

U2 - 10.1111/all.12929

DO - 10.1111/all.12929

M3 - Journal article

C2 - 27145347

SN - 0105-4538

VL - 71

SP - 1533

EP - 1539

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 11

ER -

Drug allergy passport and other documentation for patients with drug hypersensitivity: An ENDA/EAACI Drug Allergy Interest Group Position Paper

Abstract

Keywords

Access to Document

Fingerprint

Cite this